Selected videos of the 54th ASCO Congress

1-5 June 2018, Chicago, USA

The Editors of the 54th ASCO Congress Medicom Conference Report, Dr Erlinda Gordon and Dr Sant Chawla, congratulate ASCO with this year’s theme ‚ÄúDelivering Discoveries: Expanding the Reach of Precision Medicine‚ÄĚ for another successful and well-attended meeting.¬†

The highlights of the ASCO2018 annual meeting are presented in the ASCO2018 Medicom Conference Report, and include advances in screening and biomarker development for numerous types of cancer. A major theme in the report is the mixed results on whether to use monotherapy or combination therapy. Another highlight is the successful use of CAR T-cell therapy in blood cancers.

The ASCO2018 Medicom Conference Report also includes two Editor selected ASCO2018 Congress videos per chapter.

Breast Cancer

Lung Cancer

Capivasertib plus paclitaxel increases PFS compared with paclitaxel alone

Denosumab improves DFS in postmenopausal women with Breast Cancer

Pembrolizumab improves survival, reduces toxicity over chemotherapy in low PD-L1‚Äďexpressing NSCLC

Frontline pembrolizumab and chemotherapy a new standard of care in metastatic squamous NSCLC

Multiple Myeloma

Melanoma

BCMA-directed CAR T cells yield deep, durable continued from page 1A responses in relapsed/refractory Multiple Myeloma

Once-weekly dosing with carfilzomib promising for relapsed/refractory Multiple Myeloma

Adjuvant Nivolumab Continues to Outperform High-Dose Ipilimumab in Resected Stage III/IV Melanoma

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Sarcoma

Hematologic Malignancies

Regorafenib shows promise in osteosarcoma, no benefit in Liposarcoma

Maintenance therapy improves outcomes in Rhabdomyosarcoma

Studies help inform optimal use of 
CD19-Targeted CAR T-cell therapy in

Non-chemo/immunotherapy combination efficacious for advanced follicular lymphoma in RELEVANCE Trial

Developmental Therapeutics-Immunotherapy

Immunotherapy now standard for some patients with CRC

Development of a cell-free DNA multicancer screening test

LOXO-292 phase I results show promise in the treatment of RET-altered Cancers

Neck and Head Cancer

Small molecule GC4419 reduces duration of severe oral mucositis in patients receiving radiation for Head and Neck Cancers

Colorectal Cancer

Where we stand with immunotherapy in colorectal cancer: MMR tumours

Genitourinary Cancer

Some patients with mRCC can avoid nephrectomy, receive sunitinib alone